|
Roger G. Mills, M.D. was appointed Executive Vice President, Development, effective June 30, 2006. Prior to joining us, Dr. Mills held the position of Vice President, Development at Pfizer Global R&D for a five-year period. In this capacity, he was responsible for the management and direction of drug development activities at the Pfizer site in La Jolla, California, and played a key role in the development of Sutent�, a new multikinase inhibitor for patients with advanced renal cell carcinoma and gastrointestinal stromal tumors. Prior to joining Pfizer, Dr. Mills held senior clinical management positions at Gilead, where he served as project leader in the development of Tamiflu�, a leading treatment for influenza, and at Abbott Laboratories, where he played an important role in the development of antiviral drugs. Earlier in his career, he held several senior positions at the Wellcome Foundation, including Scientific Advisor for Group Marketing and Therapeutic Area Head, Cardiovascular Marketing. Dr. Mills received his medical degree at the Charing Cross Hospital Medical School in London and his specialized medical training at the Royal College of General Practitioners in London.
| 